Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Letrozole plus afatinib versus letrozole alone in first-line advanced ER-positive, HER2-negative postmenopausal breast cancer with low estrogen receptor expression
2013-002192-18Phase 2Completed
- Sponsor
- Translational Research In Oncology
- Start
- Sep 2013
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in breast cancer comparing Letrozole plus afatinib with Letrozole alone (2 arms). Primary endpoint: Progression-free survival. Started Sep 2013; status: completed.
02
Drugs
afatinibletrozole
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2013-002192-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002192-18.